Skip to content
Seastart Medical Logo
  • The Problem
  • Our Solution
  • QUELimmune
  • Pipeline
  • About
  • Investors
  • News
  • Contact
  • The Problem
  • Our Solution
  • QUELimmune
  • Pipeline
  • About
  • Investors
  • News
  • Contact
for healthcare professionals

Category: Manuscript

SAVE Registry: Early Experience in Pediatric AKI

SCD-PED vs. WE-ROCK Outcomes Analysis

Projected Hospitalization Cost Model of SCD-PED in Pediatric AKI

Impact of SCD on Neutrophil to Lymphocyte Ratio (NLR)

SCD Use in Transplant

SCD Mechanism of Action

Case Report: SCD Use in Toxic Shock Syndrome

Case Report: SCD Use in Hepatorenal Syndrome (HRS)

Editorial: SCD Use in Heart Failure

SCD-PED-01 & PED-02 Pooled Analyses

← older
Seastart Medical Logo

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Our first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic-like condition in critically ill pediatric patients. Our Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.  We are currently conducting a pivotal trial of our SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

  • The Problem
  • Our Solution
  • QUELimmune
  • Pipeline
  • About
  • Investors
  • News
  • Contact
  • The Problem
  • Our Solution
  • QUELimmune
  • Pipeline
  • About
  • Investors
  • News
  • Contact
  • Privacy Policy
  • Terms and Conditions
  • Privacy Policy
  • Terms and Conditions

Address:
3513 Brighton Blvd
Suite 410
Denver, CO 80216

Phone:
844-427-8100

Email:
info@seastarmed.com

Follow Us:  LinkedIn Twitter

©SeaStar Medical 2026